论文部分内容阅读
目的 探讨重组人类促红细胞生成素 (rHu -Epo)防治早产儿贫血的疗效。 方法 将 33例早产儿按入院次序分成治疗组 17例 ,对照组 16例。治疗组出生第 1周即予rHu -Epo 5 0 0IU·kg-1·w-1,隔日 1次 ,每周 3次皮下注射 ,共 5周 ;对照组未予rHu -Epo治疗。两组早产儿生后第 3周开始口服铁剂 [元素铁 5mg·kg-1·d-1],必要时输血 ,共观察 7周。结果 治疗组第 2周开始网织红细胞较对照组明显升高 (P <0 0 1) ,第 3周后渐下降但与对照组比较仍有显著差异 (P <0 0 5 ) ;两组患儿出生后Hb均渐下降 ,但治疗组程度较轻 ,最低Hb值较对照组高 (P <0 0 1) ,达最低Hb值的时间较对照组早 (P <0 0 1)。治疗组血清铁蛋白第 2周开始较对照组低 (P <0 0 1)。治疗组输血率与对照组比较明显减少 (P <0 0 5 )。观察期末治疗组早产儿体重增长的速率较对照组高(P <0 0 5 )。结论 早期大剂量rHu -Epo能减轻早产儿贫血的程度 ,减少或避免输血 ;体内充足的铁储备是确保rHu -Epo疗效的重要因素
Objective To investigate the effect of recombinant human erythropoietin (rHu-Epo) on the prevention and treatment of anemia in premature infants. Methods 33 cases of premature infants were divided into treatment group according to admission order 17 cases, control group 16 cases. The rHu-Epo 500 IU · kg-1 · w-1 was administered in the first week of treatment in the first week of the study, once every other day for 3 weeks and subcutaneously for 5 weeks. The control group was not treated with rHu-Epo. The two groups of preterm infants started oral administration of iron [5 mg · kg-1 · d-1] 3 weeks after birth, if necessary, blood transfusion, were observed for 7 weeks. Results At the beginning of the second week, the number of reticulocytes in the treatment group was significantly higher than that in the control group (P <0.01) and gradually decreased after the third week (P <0.05) Hb decreased gradually after birth, but the treatment group was less severe, the lowest Hb was higher (P <0.01) and the lowest Hb was earlier (P <0.01) than the control group. Serum ferritin in the treatment group began to be lower than that in the control group from the second week (P <0.01). Blood transfusion rate in the treatment group was significantly decreased compared with the control group (P <0 05). At the end of the observation period, the rate of body weight gain in the treatment group was higher than that in the control group (P <0.05). Conclusion Early high-dose rHu-Epo can reduce the degree of anemia in preterm infants and reduce or avoid blood transfusions. Adequate iron reserve in vivo is an important factor to ensure the efficacy of rHu-Epo